



Subsidiary of CytoMed Therapeutics  
(NASDAQ:GDTC)

IPSC Depository Sdn Bhd (1332047-T)

Head Office & Manufacturing Facility:  
No. 12, Jalan Permas 9/16,  
Bandar Baru Permas Jaya, 81750  
Johor.

To contact us, please email to: [enquiry@ipscbank.sg](mailto:enquiry@ipscbank.sg)

Date: 29<sup>th</sup> May 2024

## Dear Valued Customers

Based in Johor, IPSC Depository Sdn Bhd is a subsidiary of CytoMed Therapeutics Limited, a biopharmaceutical company listed on NASDAQ (ticker: GDTC) focused on patented cellular immunotherapies to treat various types of cancers both blood and solid tumours including Chimeric Antigen Receptor T ("CAR T") cell therapy which is now undergoing clinical trial in Singapore. We also have research collaborations with international institutions including MD Anderson Cancer Centre in the US. Patents for our technologies have been granted including in Malaysia, China, US and Japan.

The immediate task of IPSC Depository is two-fold. First, to restore trust and confidence of former customers of Cellsafe by focusing on service quality and continuing cryopreservation of their existing Cord Blood Units ("CBU"). This means in the near term, we will not be accepting new customers, or will be very selective of potential new customers. Our second priority is to better serve existing customers by repurposing their CBU to potentially handle a wide range of common cancers - both blood and solid tumours. We will do so at affordable cost through new service agreement subject to doctors' advice and local regulations.

Traditionally, cord blood banking involves cryopreserving the blood stem cells in the baby's umbilical cord, which is useful in the treatment of mainly blood disorders including hematopoietic stem cell transplantation for leukemia. The CBU however contains many cell types including mononuclear cells which encompass a further variety of cell types, including immune cells such as gamma delta T cells. Gamma delta T cells are a rare subset of white blood cells with the potential to treat various cancers, including solid tumours, with no requirement for donor-recipient match of their Human Leukocyte Antigen ("HLA"). This means any relative can potentially benefit from this, unlike current cord blood banking practices, which require HLA matching to ascertain suitability for non-self recipient transplant. Such gamma delta T cells can be further processed into CAR T cells, the subject of many clinical cancer trials in the world. Today, there are abundant scientific discoveries, publications and clinical trials by reputable institutions and researchers internationally on cell

**Private & Confidential**

*Advancing Cellular Immunotherapy to Treat Cancer  
Pioneering Stem Cell Research & Therapy*



Subsidiary of CytoMed Therapeutics  
(NASDAQ:GDTC)

**IPSC Depository Sdn Bhd (1332047-T)**

Head Office & Manufacturing Facility:  
No. 12, Jalan Permas 9/16,  
Bandar Baru Permas Jaya, 81750  
Johor.

*To contact us, please email to: [enquiry@ipscbank.sg](mailto:enquiry@ipscbank.sg)*

therapies. All this means the banked CBU now has greater potential use and a new lease of life. Importantly if the banked CBU is no longer viable for whatever reasons, such gamma delta T cells can still be obtained from peripheral blood of the customer or the parents or siblings with no need for HLA matching.

Subject to the terms and conditions of the new service agreement, we will continue to provide cryopreservation of the existing CBU at an affordable cost of RM 28 per month as we are also scientifically skilled in traditional cord blood banking technology. While cord blood is primarily used in hematopoietic cell transplantation, the development of novel cell therapy products from cord blood is a growing and developing medical field. Compared to adult blood, cord blood is characterised by a higher percentage of hematopoietic stem cells. Non-hematologic cells such as mesenchymal stem cells residing in cord blood also have potential in regenerative medicine, inflammatory and autoimmune conditions.

In conclusion, as research advances, ethical and logistical challenges are addressed, the full potential of cord blood in transforming medical treatments will continue to unfold. We will explore the potential therapeutic usage of these new advanced technologies to provide cellular cancer therapeutics from stored cord blood, for customers in need, in collaboration with their doctors for adjunct therapy and our network of international scientists and clinicians. We have our own cGMP laboratory, scientists, financial resources and protective patents. In simple terms, we repurpose your CBU to potentially treat more diseases in addition to the traditional use of CBU to treat blood lineage disorders i.e. “ Cord Blood for Cancer “.

We will be holding several virtual and in-person forums to meet our valuable customers. Our concierge email is [cellsafe-enquiry@ipscbank.sg](mailto:cellsafe-enquiry@ipscbank.sg).

Yours sincerely,

Evelyn Tan  
Director & CEO  
IPSC Depository Sdn Bhd

**Private & Confidential**

*Advancing Cellular Immunotherapy to Treat Cancer  
Pioneering Stem Cell Research & Therapy*




Subsidiary of CytoMed Therapeutics  
(NASDAQ:GDTC)

IPSC Depository Sdn Bhd (1332047-T)

Head Office & Manufacturing Facility:  
No. 12, Jalan Permas 9/16,  
Bandar Baru Permas Jaya, 81750  
Johor.

To contact us, please email to: [enquiry@ipscbank.sg](mailto:enquiry@ipscbank.sg)



**Private & Confidential**

*Advancing Cellular Immunotherapy to Treat Cancer  
Pioneering Stem Cell Research & Therapy*



Subsidiary of CytoMed Therapeutics  
(NASDAQ:GDTC)

IPSC Depository Sdn Bhd (1332047-T)

Head Office & Manufacturing Facility:  
No. 12, Jalan Permas 9/16,  
Bandar Baru Permas Jaya, 81750  
Johor.

To contact us, please email to: [enquiry@ipscbank.sg](mailto:enquiry@ipscbank.sg)



**Private & Confidential**

*Advancing Cellular Immunotherapy to Treat Cancer  
Pioneering Stem Cell Research & Therapy*